• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美托洛尔对梗阻性肥厚型心肌病患者运动血液动力学的影响。

Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.

机构信息

Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.

Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.

出版信息

J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024.

DOI:10.1016/j.jacc.2022.02.024
PMID:35450573
Abstract

BACKGROUND

The relationship between exercise hemodynamics, loading conditions, and medical treatment in patients with obstructive hypertrophic cardiomyopathy (HCM) is incompletely understood.

OBJECTIVES

This study aimed to investigate the effect of metoprolol on invasive hemodynamic parameters at rest and during exercise in patients with obstructive HCM.

METHODS

This randomized, double-blind, placebo-controlled crossover trial enrolled 28 patients with obstructive HCM and New York Heart Association functional class ≥II. Patients were randomized to initiate either metoprolol 150 mg or placebo for 2 consecutive 2-week periods. Right-heart catheterization and echocardiography were performed at rest and during exercise at the end of each treatment period. The primary outcome was the difference in pulmonary capillary wedge pressure (ΔPCWP) between peak exercise and rest.

RESULTS

No treatment effect on ΔPCWP was observed between metoprolol and placebo treatment (21 ± 9 mm Hg vs 23 ± 9 mm Hg; P = 0.12). At rest, metoprolol lowered heart rate (P < 0.0001), left ventricular outflow tract (LVOT) gradient (P = 0.01), and increased left ventricular end-diastolic volume (P = 0.02) and stroke volume (SV) (+6.4; 95% CI: 0.02-17.7; P = 0.049). During peak exercise, metoprolol was associated with a lower heart rate (P < 0.0001), a lower LVOT gradient (P = 0.0005), lesser degree of mitral regurgitation (P = 0.004), and increased SV (+9 mL; 95% CI: 2-15 mL; P = 0.008).

CONCLUSIONS

In patients with obstructive HCM, exercise was associated with an abnormal rise in PCWP, which was unaffected by metoprolol. However, metoprolol increased SV at rest and peak exercise following changes in end-diastolic volume, LVOT gradient, and degree of mitral regurgitation. (The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy [TEMPO]; NCT03532802).

摘要

背景

运动血液动力学、负荷条件与梗阻性肥厚型心肌病(HCM)患者的药物治疗之间的关系尚未完全阐明。

目的

本研究旨在探讨美托洛尔对梗阻性 HCM 患者静息和运动时的有创血液动力学参数的影响。

方法

这是一项随机、双盲、安慰剂对照的交叉试验,纳入了 28 例纽约心脏协会功能分级≥Ⅱ级的梗阻性 HCM 患者。患者被随机分为连续 2 个 2 周的美托洛尔 150mg 或安慰剂治疗期。在每个治疗期末,进行右心导管检查和超声心动图检查,以评估静息和运动时的情况。主要结局是运动峰值时与静息时的肺毛细血管楔压(PCWP)差值。

结果

美托洛尔和安慰剂治疗之间的 PCWP 差值无治疗效果(21±9mmHg 比 23±9mmHg;P=0.12)。在静息状态下,美托洛尔降低了心率(P<0.0001)、左心室流出道(LVOT)梯度(P=0.01),并增加了左心室舒张末期容积(P=0.02)和每搏量(SV)(+6.4;95%CI:0.02-17.7;P=0.049)。在运动峰值时,美托洛尔与较低的心率(P<0.0001)、较低的 LVOT 梯度(P=0.0005)、较轻的二尖瓣反流(P=0.004)和增加的 SV(+9mL;95%CI:2-15mL;P=0.008)相关。

结论

在梗阻性 HCM 患者中,运动与 PCWP 的异常升高相关,而美托洛尔对此无影响。然而,美托洛尔增加了静息和运动时的 SV,这与舒张末期容积、LVOT 梯度和二尖瓣反流程度的变化有关。(肥厚型梗阻性心肌病患者中美托洛尔的作用 [TEMPO];NCT03532802)。

相似文献

1
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.美托洛尔对梗阻性肥厚型心肌病患者运动血液动力学的影响。
J Am Coll Cardiol. 2022 Apr 26;79(16):1565-1575. doi: 10.1016/j.jacc.2022.02.024.
2
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.随机试验米索洛尔治疗梗阻性肥厚型心肌病患者。
J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065.
3
Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy.美托洛尔改善梗阻性肥厚型心肌病患者静息和运动时的左心室纵向应变。
J Am Soc Echocardiogr. 2023 Feb;36(2):196-204. doi: 10.1016/j.echo.2022.09.008. Epub 2022 Sep 19.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病(EXPLORER-HCM)的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
5
Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics.无症状肥厚型心肌病运动时的矛盾反应:流出道梗阻动力学的新描述。
J Am Coll Cardiol. 2013 Aug 27;62(9):842-50. doi: 10.1016/j.jacc.2013.06.007. Epub 2013 Jun 27.
6
Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics.肥厚型心肌病的运动能力。每搏输出量限制、心率及舒张期充盈特征的作用。
Circulation. 1995 Nov 15;92(10):2886-94. doi: 10.1161/01.cir.92.10.2886.
7
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.肥厚型心肌病患者行间隔心肌切除术的治疗:VALOR-HCM 随机临床试验第 56 周的结果。
JAMA Cardiol. 2023 Oct 1;8(10):968-977. doi: 10.1001/jamacardio.2023.3342.
8
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy.美托洛尔长期治疗充血性心力衰竭后运动射血分数增加及心脏重构逆转:一项针对缺血性或特发性扩张型心肌病所致轻至中度心力衰竭的随机、分层、双盲、安慰剂对照试验。
Eur J Heart Fail. 2003 Oct;5(5):679-91. doi: 10.1016/s1388-9842(03)00105-3.
9
First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.经皮二尖瓣瓣叶切开术作为有症状梗阻性肥厚型心肌病的一线治疗的初步经验。
J Am Coll Cardiol. 2016 Jun 21;67(24):2811-8. doi: 10.1016/j.jacc.2016.03.587.
10
Impact of exercise-induced mitral regurgitation on hypertrophic cardiomyopathy outcomes.运动诱发的二尖瓣反流对肥厚型心肌病结局的影响。
Eur Heart J Cardiovasc Imaging. 2016 Oct;17(10):1110-7. doi: 10.1093/ehjci/jev242. Epub 2015 Oct 16.

引用本文的文献

1
Cardiac Hypertrophy: A Comprehensive Review from Prenatal Life to Young Adulthood.心脏肥大:从胎儿期到青年期的全面综述
Children (Basel). 2025 Jul 28;12(8):989. doi: 10.3390/children12080989.
2
Hypertrophic cardiomyopathy.肥厚型心肌病
Nat Rev Dis Primers. 2025 Aug 14;11(1):58. doi: 10.1038/s41572-025-00643-0.
3
Impact of metoprolol combined with spironolactone on cardiac function in patients with coronary heart disease complicated by heart failure.美托洛尔联合螺内酯对冠心病合并心力衰竭患者心功能的影响
Am J Transl Res. 2025 Jan 15;17(1):664-673. doi: 10.62347/WWQN9188. eCollection 2025.
4
Hemodynamics in Left-Sided Cardiomyopathies.左心心肌病的血流动力学
Rev Cardiovasc Med. 2024 Dec 24;25(12):455. doi: 10.31083/j.rcm2512455. eCollection 2024 Dec.
5
Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.肥厚型心肌病心源性休克的个体化治疗:探索新兴策略
J Cardiovasc Dev Dis. 2024 Dec 11;11(12):401. doi: 10.3390/jcdd11120401.
6
The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review.心肌肌球蛋白抑制剂在肥厚型心肌病管理中的临床应用:一项范围综述。
Heart Fail Rev. 2025 Mar;30(2):453-467. doi: 10.1007/s10741-024-10476-w. Epub 2024 Dec 17.
7
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.梗阻性肥厚型心肌病:从基因洞察到马伐卡坦、阿非卡坦及其他药物的多模式治疗方法
Egypt Heart J. 2024 Dec 7;76(1):156. doi: 10.1186/s43044-024-00587-y.
8
Management of Intraventricular Gradient in Patients With Aortic Stenosis.主动脉瓣狭窄患者脑室内梯度的管理。
JACC Case Rep. 2024 Nov 6;29(21):102696. doi: 10.1016/j.jaccas.2024.102696.
9
Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review.肥厚型心肌病的诊断与治疗进展:综述
J Cardiovasc Dev Dis. 2024 Sep 18;11(9):290. doi: 10.3390/jcdd11090290.
10
Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy.阻塞性肥厚型心肌病患者报告的症状、影响和治疗目标的定性访谈研究。
BMJ Open. 2024 Sep 17;14(9):e081323. doi: 10.1136/bmjopen-2023-081323.